autoimmune-995x60 autoimmune-995x60

FEATURED ARTICLES

How One Rare Disease Firm Merged Gene Therapy With Patient Centricity
How One Rare Disease Firm Merged Gene Therapy With Patient Centricity

Abeona Therapeutics is named after the Roman goddess who was the protector of children as they start out on their journey. Since launching as a private company in 2013, Abeona has partnered with a dozen international foundations to fund its development efforts. Currently it is seeking a treatment for children with Sanfilippo Syndrome, and engaging caregivers to determine how to best meet the needs of patients taking part in trials.

More Featured Articles

WHITE PAPERS AND CASE STUDIES

  • Critical Success Factors For Clinical Trials Of Immune Checkpoint Inhibitors
    Critical Success Factors For Clinical Trials Of Immune Checkpoint Inhibitors

    Oncologists and their patients have had reason recently to be encouraged by the launch of immune checkpoint inhibitors (ICIs) for the treatment of several difficult-to-treat diseases, including metastatic melanoma and non-small cell lung cancer. These novel agents activate the human immune response against antigens expressed on tumor cells, and the science has generated excitement among physicians, patients, the media and researchers.

More White Papers & Case Studies

NEWS

More News